This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Willing to sign written informed consent;
Chronic HDV history with at least 6 months;
HDV RNA ≥500 IU/mL at screening;
ALT >1ULN and <10×ULN;
Concomitant decompensated cirrhosis;
Previous or current HCC or suspicion for HCC;
Participants with history of alcoholic liver disease, nonalcoholic steatohepatitis or other clinically significant chronic liver diseases not caused by HDV/HBV;
Participants with active hepatitis C infection, or HIV infection;